Novartis ESMO Event Presentation

Exposure-adjusted safety data show even better tolerability in this earlier line of treatment than was seen in the VISION study Incidence rate per 100 subject-time years PSMAfore Incidence rate per 100 subject-time years VISION 60 88 39 53 AES (Grade ≥3) Treatment related AEs (Grade ≥3) 17 SAES 33 ~2,000 patient-years of exposure in VISION, PSMAfore and post-marketing experience support favorable safety and tolerability profile of Pluvicto 26 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation